View in EDS HTML Full Text PDF Full Text

Enfortumab vedotin versus platinum rechallenge in post‐platinum, post‐pembrolizumab advanced urothelial carcinoma: A multicenter propensity score‐matched study.

Saved in:
Bibliographic Details
Title: Enfortumab vedotin versus platinum rechallenge in post‐platinum, post‐pembrolizumab advanced urothelial carcinoma: A multicenter propensity score‐matched study.
Authors: Taguchi, Satoru1 (AUTHOR), Kawai, Taketo1,2 (AUTHOR) taketokawai@yahoo.co.jp, Ambe, Yoshiki1 (AUTHOR), Kishitani, Kenjiro1 (AUTHOR), Sugimoto, Kazuma3 (AUTHOR), Miyakawa, Jimpei3 (AUTHOR), Nakamura, Yu3 (AUTHOR), Noda, Michio2 (AUTHOR), Kaneko, Tomoyuki2 (AUTHOR), Kamei, Jun1,4 (AUTHOR), Obinata, Daisuke5 (AUTHOR), Yamaguchi, Kenya5 (AUTHOR), Kakutani, Shigenori6 (AUTHOR), Furuya, Yoshitsune7 (AUTHOR), Sato, Yujiro7 (AUTHOR), Uemura, Yukari8 (AUTHOR), Akiyama, Yoshiyuki1 (AUTHOR), Yamada, Yuta1 (AUTHOR), Sato, Yusuke1 (AUTHOR), Yamada, Daisuke1 (AUTHOR)
Source: International Journal of Urology. Dec2023, Vol. 30 Issue 12, p1180-1186. 7p.
Database: Academic Search Ultimate
Full text is not displayed to guests.
Description
ISSN:09198172
DOI:10.1111/iju.15300